10170 Church Ranch Way
Suite 100
Westminster, CO 80021
United States
720 940 2200
https://www.arcabio.com
Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 4
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Mr. Thomas A. Keuer | President, COO & Principal Executive Officer | 400,8k | N/D | 1959 |
Mr. C. Jeffrey Dekker CPA | CFO, Treasurer & Company Secretary | 323,07k | N/D | 1965 |
ARCA biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of targeted therapies for cardiovascular diseases. Its lead product candidate is Gencaro, a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with heart failure. It is developing Recombinant Nematode Anticoagulant Protein c2, a protein therapeutic that is in Phase IIb clinical trial for the treatment for COVID-19. The company has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.
L'ISS Governance QualityScore di ARCA biopharma, Inc. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.